Index

Acute flaccid paralysis (AFP), 217–219
Acute respiratory distress syndrome (ARDS), 108
Addictions, vaccines to treat, 180–182
Adenoviruses, 136
  development of vaccines, 99–111
Adjuvant and formulation systems, 30–35
Adolescent/young adult, vaccinations for, 8
Advisory Committee on Causality Assessment (ACCA), 209
Advisory Committee on Dangerous Pathogens (ACDP) for the Health and Safety Executive (HSE), 163–164
Advisory Committee on Immunization Practices (ACIP) in US, 104–105, 108
Almond J *see* **Moingeon P**
Alzheimer's dementia, 8
Anthrax (*Bacillus anthracis*), 170–171
Antigen
  particulate formulations, 33–35
  presenting cells (APC), 32–34, 151
Antitumour immunity, 149–162
Archeosomes, 33
Armstrong A *see* **Dermime S**
Artemesinin derivatives, 60
Atherosclerotic heart disease, 8

Bacillus Calmette-Guérin (BCG) vaccination, limitations of, 74–76, 82
  variable efficacy, 50
Bacterial live vector vaccines, 10
Bacterial human enteric pathogens vaccines against, 113–123
Bacterial pathogen genomics and vaccines: **Moxon R, Rappuoli R,** 45–58
Bacterial vectors, 38–39
Beverley PCL *see* **Salisbury DM**
Beverley PCL: Immunology of vaccination, 15–28
Bill and Melinda Gates Foundation, 68
  and GAVI, 9
Bioethical issues
  in vaccine development, 11
  of contraceptive vaccines, 177, 179–180
Bioinformatics, 48–49
Biotechnology revolution, 1
Bioterrorism, 10
Blood stage vaccines, malaria, 66–67
Burkitt's lymphoma and EBV, 134–135

Campbell JD *see* **Levine MM**
Campylobacter, 115, 116, 118
Canarypox
  vaccine (ALVAC), 104
  virus vectors and HCMV, 133
Cancer testis antigens, 153, 154
Cancer vaccines and immunotherapy: **Dermime S, Armstrong A, Hawkins RE, Stern PL,** 149–162
Candidate antigens, facilitating the discovery of, 48–54
Capron A, Capron M, Riveau G: Vaccine development against schistosomiasis from concepts to clinical trials, 139–148
Capron M *see* **Capron A**
Carmichael AJ *see* **Wills MR**
Ceasing vaccination for polio,
  hazards of, 219–221
  strategies for, 221
Cellular (T-cell) immune response, 87–90
Certificate of eradication, 217–219
Cessation of programmes after eradication, 213–224
Chickenpox *see* Varicella zoster virus (VZV)
Chlamydia pneumoniae (linked to IHD), 208
Cholera, 114–115, 117–119
Chronic diseases, vaccines against, 7–8
Chronic obstructive pulmonary disease (COPD), 108
Circumsporozoite protein (CS), 62, 63
Clades of HIV, 92, 93–94
Clare S:*see* **Dougan G**
Classification of pathogens, 164
Clinical trials of vaccines for
  dangerous pathogens, 169–170
  schistosome vaccines, 145–146
  tuberculosis , 82–83
  types of, 1–3
Clostridium botulinum, 170
Cocaine, anti-cocaine vaccine, 180–181
Common colds, development of vaccines, 99–111
Competence stimulating peptide (CSP), 50
Congenital rubella syndrome (CRS), 213

© The British Council 2002

Contraceptive vaccines, 176–180
ethics of development, 177, 179–180
Coronaviruses, development of vaccines against, 99–111
Cytomegalovirus, 208
development of vaccines against, 99–111
Cytotoxic T lymphocyte vaccines for HIV, 90–91
broadening the response, 94–95

Dangerous pathogenss, vaccines against, 163–173
animal models, 168–169
clinical trials, 169–170
classification of, 164
development of vaccines against, 166–167
formulation options, 170–171
need for vaccines against, 165–166
R&D difficulties, 167–168, 171
surrogate markers of efficacy, 169–170
Dapsone/chlorproguanil, 60
de Taisne C *see* **Moingeon P**
Delivery technologies for human vaccines: **Moingeon P, de Taisne C, Almond J,** 29–44
Delivery technologies for vaccines
desirability of non-parenteral routes, 4–5
for dangerous pathogens, 171
need for improvements, 29–32
new methods, 40–42
non-industrialised countries, 9–10
Dendritic cells (DCs) and exosomes, cancer vaccines, 40, 157–158
Dendritic cells and T-cell immune response to HIV, 89
Dengue, 208
Dental decay, anti-dental caries vaccines, 182–184
Dermime S, Armstrong A, Hawkins RE, Stern PL: Cancer vaccines and immunotherapy, 149–162
Design and tests of an HIV vaccine: **McMichael A, Mwau M, Hanke T,** 87–98
Developing market vaccines, 7
Development of vaccines against common colds: **Olszewska W, Zambon M, Openshaw PJM,** 99–111
Differentiation antigens, cancer, 153, 154
Disabled infectious single cycle (DISC) vaccines, 128
District Immunisation Co-ordinators (DICs), 204
DNA prime/live vector boost, 10
DNA vaccines, 10
DNA virus (persistent) infections, vaccines against, 125–138
DNA-based cancer vaccines, 157
Dougan G, Huett A, Clare S: Vaccines against human enteric bacterial pathogens, 113–123

Ebola virus, 165, 170, 171
Economic factors in enteric bacterial pathogen vaccine developmnt, 115–116
Economics of vaccine development, 5–7, 45–46, 205–206
Elderly, vaccinations for, 8
Encephalitic viruses, 170
Enteric bacterial pathogens, vaccines against human, 113–123
Enzyme-linked immunospot (ELISPOT) assay, 63, 64, 159
Epstein-Barr virus (EBV), 125, 133–135, 208
Eradication and cessation of programmes: **Minor PD,** 213–224
Erythrocyte membrane protein (EMP), 66
Escherichia coli, 114–115, 118–119
O157:H7, evolution of, 165
Ethics of vaccine development, 11
contraceptive vaccines, 177, 179–180
Exanthem roseola, 135
Exosomes and dendritic cells (DCs), vaccines for cancer patients, 40
Expanded Program on Immunization (EPI), 8, 115, 120
Experimental challenge studies, 2
Expression library immunisation (ELI), 51

Fertilization blocking vaccines, 178–179
Flea bite transmission of plague, 165, 168
Follicle stimulating hormone (FSH), contraceptive vaccines, 177–178

Gastrointestinal bacterial pathogens, vaccines against, 113–123
Generic 'platform' technologies in vaccine development, 10–11
Genomics
manipulation, reverse genetics, 104
bacterial pathogen, and vaccines, 45–58
Global Alliance for Vaccines and Immunization (GAVI), 8–9, 206
Global Fund for Children's vaccines, 9
Global market vaccines, 6
Global Poliomyelitis Eradication Initiative, 223

Global warming increasing the proportion of the world climatically suitable for transmission, 60
Globalization of infectious diseases, 9–10
Gonadotrophin releasing hormone (GnRH) contraceptive vaccines, 177–178
Group B streptococci, 208

Haemagglutinin (HA), influenza vaccines and, 104
Hanke T *see* **McMichael A**
Hawkins RE *see* **Dermime S**
Health Services, role of, in vaccine development, 205
Helicobacter pylori, 120, 208
Herpes simplex virus, 125–128, 208
Herpes zoster, 208
Hill ASV *see* **Moorthy V**
Hodgkin's disease and EBV, 134–135
Holotoxins, 32
Huett A *see* **Dougan G**
Human chorionic gonadotrophin (hCG), contraceptive vaccines, 178
Human cytomegalovirus (HCMV), 125, 131–133
Human herpes viruses 6–8 (HHV-6,HHV-7, HHV-8), 135
Human immunodeficiency virus (HIV), 208
  adaptation, 165
  cellular (T-cell) immune responses, 89–90
  exposed uninfected humans, 91
  infection and tuberculosis incidence, 74
  vaccine
    design and tests of, 87–98
    development, 163–173
    phase I trials, 92–93
Human papilloma viruses, 208
Human tumour antigens
  identification and classification, 152–155
  immune recognition, 151–152
Hygiene hypothesis, 24

Ideal vaccines, 15–17, 87–89
Immune responses, appropriate, 22–24
  heterogeneity, 22–23
  T-cell, 23–24
Immune responses, initiation, 17–21
  antigen processing, 18
  danger signals, 17–18
  migration and maturation, 18–21
Immune surveillance hypothesis, 152
Immunisation Monitoring Programme Active (IMPACT) system, in Canada, 209
Immunisation
  and vaccines, overview of, 1–13
  programme, delivery of the UK, 202–203
  schedules of the 'busy' infant/toddler, 4
Immunity
  effector mechanisms and clinical expression of, schistosomias, 140–142
  types stimulated by 'ideal' vaccine, 87–89
  vaccine-induced (cancer), evaluation and monitoring of, 158–159
    potentiating, 159–160
Immunological memory, 21–22
Immunology of vaccination: **Beverley PCL**, 15–28
Immunotherapeutics, 175–186
  cancer vaccines, 149–162
Impeded vaccines, 6,7
  fostering development of, 7
In vitro expression technology (IVET), 52–53
Inactivated poliovaccines (IPVs), 208, 216, 221
Industrialised market vaccines, 6
Infectious mononucleosis (IM), 134–135
Influenza viruses A and B, development of vaccines against, 99–111
  intranasal attenuated, 208
Innate immunity, 87–88
Institutional Review Boards (IRBs), 11
Intranasal routes of delivery, 4–5, 208

Joint Committee on Vaccination and Immunisation (JCVI), UK, 203, 204

Kaposi's sarcoma associated herpes virus, 125–138
Killed virus vaccines, 87–88
Kotloff KL *see* **Levine MM**

Lassa fever virus, 165, 166, 170
Leprosy and BCG, 76
Levine MM, Campbell JD, Kotloff KL: Overview of vaccines and immunisation, 1–13
Life-style vaccines: **Mettens P, Monteyne P**, 175–186
Liposome-encapsulated antigens, 33, 171
Live attenuated vaccines, 87
  mycobacterial, 80–81
  RSV, 103, 104
Live recombinant vectors containing RSV antigens, 103–104
Live vaccine vector delivery, 171

Liver-stage antigens (LSA), malaria, 65–66
Lyme disease, 208

Malaria, 59–72, 208
  complications,
    blood stage vaccines, 66–67
  increasing incidence, 59–69, 208
  natural versus vaccine immunity, 61
Malaria vaccines: **Moorthy V, Hill ASV**, 59–72
Maternal immunization, respiratory viral infections, 108
Mathematical modelling to predict future disease patterns and design vaccination programmes, 204–205
Mathematical models of vaccination: **Scherer A, McLean A**, 187–199
McLean A *see* **Scherer A**
McMichael A, Mwau M, Hanke T: Design and tests of an HIV vaccine, 87–98
Memory, immunological, 21–22
Meningococcal C vaccination in UK, 8
Meningococcus group B (MenB), 208
  genomics, 54–56
Mettens P, Monteyne P: Life-style vaccines, 175–186
Miller E *see* **Salisbury DM**
Minor PD: Eradication and cessation of programmes, 213–224
Measles/mumps/rubella *see* MMR
MMR furore and monitoring, 206, 210
MMR varicella, new, 208
Models (mathematical) of vaccination, 187–199, 204–205
Modified Vaccinia virus Ankara (MVA), 64–65
Moingeon P, de Taisne C, Almond J: Delivery technologies for human vaccines, 29–44
Monteyne P *see* **Mettens P**
Moorthy V, Hill ASV: Malaria vaccines, 59–72
Moxon R, Rappuoli R: Bacterial pathogen genomics and vaccines, 45–58
Mucosal immunity, 87–88
Mucosal immunization
  for vaccine delivery, 114, 171, 107
  respiratory viral infections, 107
Mwau M *see* **McMichael A**
Mycobacterium tuberculosis see Tuberculosis (TB)
Mycobacterium vaccae, 183

Nasal and oral delivery, respiratory viral infections, 107
Naso-pharyngeal carcinoma (NPC), 134–135
National Immunisation Days (NIDs) poliovirus eradication 216, 221
Needle-free injections, 40–42
Neisseria menigitidis, 167
Neonates and respiratory viral infections, 108
Neuraminidase, influenza vaccines and, 104
Neutralising antibody, 87–88
Nicotine, anti-nicotine vaccine, 181
NicVAX from Nabi, 181
Non-living parenteral vaccines, 119–120

Olszewska W, Zambon M, Openshaw PJM: Development of vaccines against common colds, 99–111
Open reading frames (ORFs), 55
Openshaw PJM *see* **Olszewska W**
Oral and nasal delivery, 4–5, 116–117
  respiratory viral vaccines, 107
Oral poliovaccines (OPVs), 216, 221
Otitis media, 208
Over-expressed 'self' antigens, cancer, 153, 154
Overview of vaccines and immunisation: **Levine MM, Campbell JD, Kotloff KL**, 1–13

Papilloma viruses, 135
Papova viruses, 136
Parainfluenza viruses (PIV), development of vaccines against, 99–111
Parenteral delivery, 171
Parvovirus, 136
Peptide-based vaccines, cancer, 156
Persistent DNA virus infections, vaccines against, 125–138
Phase I trials, 1–2
Phase II trials, 2
Phase III trials, 2–3
Phase IV trials, 3
Plague (*Yersinia pestis*) probably evolved from *Yersinia pseudotuberculosis*, 163–173
Plant-based edible vaccines, 39–40
Plasmid DNA-based vaccines, 39
Plasmodium falciparum, life cycle and vaccine development, 59–72
Pneumonic plague *see* Plague
Polio Eradication Initiative, 8

Poliomyelitis – poliovirus eradication, 215–223
Population migrations due to conflicts, famine and economic problems, effects of, 60
Porphyromonas gingivalis, 167
Post-vaccination dynamics, 189–192, 193–194
Post-infective immunisation for prevention of zoster, 131
Pre-erythrocyte vaccines, malaria, 63–66
Pregnant and pre-pregnant vaccination, respiratory viral infections, 108
Prime boost regimen using DNA and recombinant pox virus, 87
Program for Appropriate Technology in Health (PATH), 68
Prostate cancer, 177
Protection
  complete or not? 95–96
  duration of, 192–194
Public perception, 206

Rappuoli R *see* **Moxon R**
Re-emergence of poliomyelitis after eradication and responses to, 222–223
Recombinant virus-based vaccines, cancer, 156–157
Respiratory syncytial virus (RSV), 208
  special problems in development of vaccines, 99–111
Reverse vaccinology, 10
Rhinoviruses, development of vaccines against, 99–111
Riveau G *see* **Capron A**
Rockefeller Foundation and GAVI, 9
Rubella, congenital rubella syndrome (CRS), 213
Salisbury DM, Beverley PCL, Miller E: Vaccine programmes and policies, 201–211
Salmonella enterica subspecies *enterica* serovar Typhi (*S.* Typhi), 114–115, 116, 117, 120
Salmonella enterica, 114–115
Scherer A, McLean A: Mathematical models of vaccination, 187–199
Schistosoma bovis, 144
Schistosoma haematobium, 141, 144, 145
Schistosoma japonicum, 141, 144
Schistosoma mansoni, 140, 144, 145
Schistosoma mattheei, 141
Schistosome vaccine candidates selected by WHO, 143–144
Schistosomiasis, vaccine development against, from concepts to clinical trials, 139–148
Scripps Research vaccine, 181
SEREX (serologic analysis of recombinant cDNA expression libraries) 152
Serial analysis of gene expression (SAGE), 50
Sexual stage vaccines, malaria, 67
Shigella vaccines, 114–115, 117, 120
Signature-tagged mutagenesis (STM), 51–52
Sissons JGP *see* **Wills MR**
Smallpox Eradication Program, 8
Smallpox eradication, 214–215
Societal perceptions and expectations of vaccine safety, 4
Spherulites, 33
Staphyloccocal food poisoning, 114–115
STD vaccines, 8
Stern PL *see* **Dermime S**
Stewart GR *see* **Young DB**
Strategic planning for UK immunisation policy, 203–208
Streptococcus mutans, 182–184
Streptococcus pneumoniae, 167
Streptococcus sobrinus, 183
Subunit and peptide vaccines for
  RSV, 103
  malaria, 61–63
  TB, 82–83

T-cell responses, 23–24
  generating CD8+, 91–92
TA-CD from Xenova, 180–181
TA-NIC from Xenova, 181
Target populations, 8
Thrombospondin-related adhesion protein (TRAP), malaria, 65
Titball RW *see* **Williamson ED**
Tourism, spreading malaria, 60
Transcutaneous routes, 4–5
Transfersomes, 33
Transforming growth factor (TGF), 152
Tuberculosis (TB), 208
Tuberculosis vaccines: **Young DB, Stewart GR**, 73–86
  clinical trials, 82–83
  immunity to, 77–79
  new vaccine candidates, 80–82
  new vaccine prospects, 76–77

persistence and reactivation, 78–79
Tumour antigens, vaccination with, 155–158
Tumour cell-based vaccines, 155–156
Tumour-specific antigens, 153, 154
Typhoid vaccine, 114–118

Vaccination
strategies, 216–217
tumour antigens, 155–158
Vaccine candidate molecules, 45–58
Vaccine delivery methods, 29–44
dangerous pathogens, 171
desirability of non-parenteral routes, 4–5
mucosal, 114
need for improvements, 29–32
new methods, 40–42
non-industrialised countries, 9–10
respiratory viral infections, 107–108
Vaccine design and genomics, 45–58
Vaccine development against schistosomiasis from concepts to clinical trials: **Capron A, Capron M, Riveau G**, 139–148
Vaccine development, 1–11
bacterial pathogen genomics, 45–58
cancer vaccines, 149–162
common colds, 99–111
dangerous pathogens, 163–173
economics of, 5–7
generic 'platform' technologies in, 10–11
HIV vaccine, 87–98
human enteric bacterial pathogens
life-style vaccines, 175–186
malaria vaccines, 59–72
persistent DNA virus infections, 125–138
poliomyelitis, 215–223
schistosomiasis, 139–148
tumour antigens, 155–158
undercurrents retarding, 3–11
Vaccine programmes and policies: Salisbury **DM, Beverley PCL, Miller E**, 201–211
Vaccine resistance, the evolution of, 194–198
Vaccine safety, 4, 208–210
Vaccine targets beyond 2002, principal, 208
Vaccine-induced immunity – cancer
evaluation and monitoring of, 158–159
potentiating, 159–160
Vaccines against dangerous pathogens: **Williamson ED, Titball RW**, 163–173
Vaccines against human enteric bacterial pathogens: **Dougan G, Huett A, Clare S**, 113–123
Vaccines against persistent DNA virus infections: **Wills MR, Carmichael AJ, Sissons JGP**, 125–138
Vaccines
and immunisation, overview of, 1–13
for licensure soon, 208
new and almost approved, 206–208
Vaccinia
(NYVAC), 104
virus Ankara (MVA), 104
Varicella zoster virus (VZV), 125, 128–130
Vectors, 36–40
Vi polysaccharide, 120
Vibrio cholerae, 114–119
Viral antigens, cancer, 153, 155
Viral live vectors such as adenovirus, 10
Viral vectors, 35–38
Virosomes, 33

Wellcome Trust, 68
World Health Organization (WHO), 140
and GAVI, 9
recommendations in Europe, 203
Williamson ED, Titball RW: Vaccines against dangerous pathogens, 163–173
Wills MR, Carmichael AJ, Sissons JGP: Vaccines against persistent DNA virus infections, 125–138
World Bank and GAVI, 9

Yellow card system, 209
Yersinia pestis (plague) probably evolved from *Yersinia pseudotuberculosis*, 163–173
Young DB, Stewart GR: Tuberculosis vaccines, 73–86

Zambon M *see* **Olszewska W**